A recently released analysis from the Kaiser Family Foundation sheds new light on how rising drug prices are impacting patients' out-of-pocket spending on drugs, as well as the budgets of private and public payers.
A recently released analysis from the Kaiser Family Foundation (KFF) sheds new light on how rising drug prices are impacting patients' out-of-pocket spending on drugs, as well as the budgets of private and public payers.
The analysis drew from data included in the National Health Expenditures Accounts database, the Truven Health Analytics MarketScan Commercial Claims and Encounters Database, and CMS.
According to KFF, the top 50 drug products by spending in 2016 were responsible for a substantial share of total drug pending, yet they accounted for a relatively small share of total prescriptions among large employer plans (39% share of spending vs 8% share of prescriptions), Medicare Part D (43% share of spending vs 15% share of prescriptions), and Medicaid (41% share of spending vs 8% share of prescriptions).
The top 5 drugs products with the highest total spending in 2016 accounted for approximately 10% of total prescription drug spending among large employer plans, Medicare Part D, and Medicaid. Among large employers, Humira ($4.9 billion) and Enbrel ($2.4 billion), both of which have FDA-approved but unlaunched biosimilar options, were responsible for the greatest share of spending.
In Medicare Part D, Harvoni ($4.4 billion) and Revlimid ($2.6 billion) topped the spending charts for 2016, with Lantus Solostar ($2.5 billion) being the drug with the third highest spending under Part D. Medicaid spent the most on Harvoni ($2.2 billion), followed by Humira ($1.3 billion).
Humira and Enbrel also had some of the highest average out-of-pocket spending per user in both large employer plans and Medicare Part D in 2016; in employer plans, patients spent an average of $1123 and $1134 on the 2 branded drugs, respectively. In Part D, they paid $1587 on the pen presentation of Humira and $1610 on Enbrel.
Reflected in the above numbers is the fact that, on average, people covered in Medicare Part D plans spend more out of pocket than those covered through their employer plans. On average, in 2016, Medicare Part D enrollees spend $365 out of pocket on drugs, compared with $132 for those insured through large employers.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.